Home
About Us
Our Science
Join Us
Investors
Contact Us
Korro Bio hits the high notes with $91.5M Series A to run its OPERA RNA platform
Post navigation
Previous Post
Previous
Korro Bio raises $90m to fix mutations that cause diseases
Next Post
Next
Animal data in hand, Nessan Bermingham banks $91.5M for Atlas-backed RNA editing play
